LYNPARZA delivers 72% ORR in phase 3 SOLO3 trial in advanced ovarian cancer

This article was originally published here

The results were presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The results from the trial showed a statistically-significant and

The post LYNPARZA delivers 72% ORR in phase 3 SOLO3 trial in advanced ovarian cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply